Electrochemical/Electroflotation Process for Dye Wastewater Treatment

The use of dyes has become very significant across various industries such as textiles, paper, and clothing. The organic chemical composition of dyes is a major concern when discharging wastewater not only into the environment, but also within wastewater treatment plants. Dye effluent consists of high chemical oxygen demand (COD) and also color, components that require treatment before discharge. As a result, federal legislation has required industries that discharge high components in wastewater to undergo treatment within the plants. Within literature, authors have considered various biological, physical, and chemical methods of treating dye wastewater. Recently, electrocoagulation/electroflotation (ECF) has been an additional method of treatment that has been considered for the treatment of dye wastewater. Two separate studies are considered. First, Acid Yellow 11 (AY11) at a concentration of 25 mg/L (by weight) underwent treatment from three different coagulants (Alum, Ferric Sulfate, and Ferric Chloride) , under three different strengths (5 mg/L, 10 mg/L, and 15 mg/L), and two different initial pH considerations (4 and 7) for the purpose of analyzing color removal. Following the study, the results were collaborating into a response surface methodology, developing an equation for the three different coagulants. In addition, a Box-Behnken design has been setup for the purpose of considering the effects of pH, dye concentration, dye type, coagulant type and strength on the efficiency of electrocoagulation. These values will be analyzed using statistical analysis, along with toxicity study done on the effectiveness of removing toxic contaminants from the wastewater. Finally, a photo-oxidation study was completed on Acid Orange 7 (AO7) synthetic dye wastewater for the purpose of determining the effects of photo-oxidation based on dye concentration, catalyst type and dose. Langmuir-Hinshelwood coefficients were developed based on the results of this experimen

Electrochemical/Electroflotation Process for Dye Wastewater Treatment

The use of dyes has become very significant across various industries such as textiles, paper, and clothing. The organic chemical composition of dyes is a major concern when discharging wastewater not only into the environment, but also within wastewater treatment plants. Dye effluent consists of high chemical oxygen demand (COD) and also color, components that require treatment before discharge. As a result, federal legislation has required industries that discharge high components in wastewater to undergo treatment within the plants. Within literature, authors have considered various biological, physical, and chemical methods of treating dye wastewater. Recently, electrocoagulation/electroflotation (ECF) has been an additional method of treatment that has been considered for the treatment of dye wastewater. Two separate studies are considered. First, Acid Yellow 11 (AY11) at a concentration of 25 mg/L (by weight) underwent treatment from three different coagulants (Alum, Ferric Sulfate, and Ferric Chloride) , under three different strengths (5 mg/L, 10 mg/L, and 15 mg/L), and two different initial pH considerations (4 and 7) for the purpose of analyzing color removal. Following the study, the results were collaborating into a response surface methodology, developing an equation for the three different coagulants. In addition, a Box-Behnken design has been setup for the purpose of considering the effects of pH, dye concentration, dye type, coagulant type and strength on the efficiency of electrocoagulation. These values will be analyzed using statistical analysis, along with toxicity study done on the effectiveness of removing toxic contaminants from the wastewater. Finally, a photo-oxidation study was completed on Acid Orange 7 (AO7) synthetic dye wastewater for the purpose of determining the effects of photo-oxidation based on dye concentration, catalyst type and dose. Langmuir-Hinshelwood coefficients were developed based on the results of this experimen

The Effects of Chemical Coagulants on the Decolorization of Dyes by Electrocoagulation Using Response Surface Methodology (RSM)

This study assessed the efficiency of electrocoagulation (ECF) coupled with an addition of chemical coagulant to decolorize textile dye. Tests were conducted using Box Behnken methodology to vary six parameters: dye type, weight, coagulant type, dose, initial pH and current density. The combination of electrocoagulation and chemical coagulation was able to decolorize dye up to 99.42 % in 30 min of treatment time which is remarkably shorter in comparison with using conventional chemical coagulation. High color removal was found to be contingent upon the dye type and current density, along with the interactions between the current density and the coagulant dose. The addition of chemical coagulants did enhanced treatment efficiency

A Simple Analytical Formulation for Periodic Orbits in Binary Stars

An analytical approximation to periodic orbits in the circular restricted three-body problem is provided. The formulation given in this work is based in calculations known from classical mechanics, but with the addition of the necessary terms to give a fairly good approximation that we compare with simulations, resulting in a simple set of analytical expressions that solve periodic orbits on discs of binary systems without the need of solving the motion equations by numerical integrations.Comment: Accepted on MNRAS. 29 pages including 6 Figures and 4 table

Electrocoagulation in Wastewater Treatment

A review of the literature published in from 2008 to 2010 on topics related to electrochemical treatment within wastewater was presented. The review included several sections such as optimization, modeling, various wastewater treatment techniques, analytical and instrumentation, and comparison with other treatment methods

Oxidation Pond for Municipal Wastewater Treatment

This literature review examines process, design, and cost issues related to using oxidation ponds for wastewater treatment. Many of the topics have applications at either full scale or in isolation for laboratory analysis. Oxidation ponds have many advantages. The oxidation pond treatment process is natural, because it uses microorganisms such as bacteria and algae. This makes the method of treatment cost-effective in terms of its construction, maintenance, and energy requirements. Oxidation ponds are also productive, because it generates effluent that can be used for other applications. Finally, oxidation ponds can be considered a sustainable method for treatment of wastewater

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

AI is a viable alternative to high throughput screening: a 318-target study

: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection